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Peripheral artery disease (PAD) and stroke can occur as vascular complication of different anti-cancer treatment. Particularly, vascular endothelial growth factor inhibitors (VEGFI) (i.e. bevacizumab) are associated with clinical sequelae such as hypertension, stroke and thromboembolism beyond acute coronary syndromes, while BCR-ABL tyrosine-kinase inhibitor (TKIs), used for the treatment of chronic myeloid leukaemia (CML) are the main anti-neoplastic drugs involved in the development of PAD. The development of vascular toxicity is obviously influenced also by traditional cardiovascular risk and predisposing genetic factors. Vascular damage is also observed as complication of other anticancer treatment such as cyclophosphamide, antracyclines and head and neck radiotherapy.

An accurate cardiovascular risk-stratification is, thus, strongly recommended in patient candidate to anti-cancer treatment associated with higher risk of vascular complication, in order to correct CVRF and select appropriate tailored-patient strategy of treatment. Then a clinical follow-up, eventually associated to instrumental evaluation through vascular ultrasound, should be performed.

In the subsequent paragraphs we will focus on peripheral artery disease and stroke, describing etiopathogenesis, diagnosis and therapeutic management.
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Incidence and pathophysiology {#sec2-1}
-----------------------------

Peripheral artery disease (PAD) can occur as complication secondary to anticancer treatment, with an incidence of up to 30%.\[[@ref1]\] BCR-ABL tyrosine kinase inhibitor (TKI), used for the treatment of chronic myeloid leukemia (CML), is the main antineoplastic drugs involved in the development of PAD being responsible for the development of vascular adverse events. Due to the emerging resistance against imatinib, considered a "gold standard" of treatment of patients with newly diagnosed CML, more effective TKIs, including nilotinib, dasatinib, bosutinib, and ponatinib, have been developed and are successfully used in daily practice.\[[@ref2][@ref3][@ref4][@ref5]\] Their superior efficacy with a major antileukemic activity is, however, accompanied by the development of adverse effects, due to the expression of several targets also in nonhematopoietic cells. Vascular damage is an emerging type of clinically relevant complications in patients receiving second- or third-generation BCR-ABL1 TKIs and includes coronary artery disease, cerebral ischemic disease (stroke), and PAD.\[[@ref6][@ref7][@ref8][@ref9]\] The exact incidence of vascular complications is still debated, but according to the most studies, emerging data are the following: (1) the frequency of vascular adverse events increases over time, (2) it is higher in patients treated with higher doses of nilotinib ((800 vs. 600 mg daily) or ponatinib (45 mg vs. 30 or 15 mg daily), and (3) there is a certain correlation between preexisting cardiovascular risk factors (CVRF) and vascular complications.\[[@ref10][@ref11][@ref12][@ref13]\] The various TKIs have distinct vascular safety profiles, most likely due to each compound\'s different kinase inhibition profiles and nonkinase targets. Even if nilotinib and ponatinib are the BCR-ABL TKIs more involved in the development of vascular damage, recent data suggest that vascular disease can also occur in CML patients treated with dasatinib or bosutinib, but with a lower incidence (\<5% of patients).\[[@ref14][@ref15]\] On the contrary, the incidence of vascular complications in patients treated with imatinib appears to be low, interestingly \<1% of patients.\[[@ref13]\] Imatinib was found to improve the fasting blood glucose level; thus, it can explain a possible protective effect of imatinib on the formation of atherosclerotic plaque and the related cardiovascular diseases.\[[@ref16]\] When evaluating the risk of PAD development in such patients treated with BRC-ABL TKIs, different factors have to be considered \[[Table 1](#T1){ref-type="table"}\]. First, the presence of preexisting CVRF, such as hypertension, diabetes mellitus, dyslipidemia, smoke, and preexisting vascular disease. Another relevant factor affecting the development of vascular complication is the dose of TKIs, with increased risk at higher doses. Therefore, lowering the dose of drug administered can reduce the incidence of vascular adverse effects. Moreover, shorting the time of exposure to these TKIs can lower the risk of PAD and stroke. In addition, the sequential use of certain TKIs, such as nilotinib and ponatinib, increases the risk of vascular complications; thus, it has been suggested to avoid it if possible.\[[@ref10][@ref17]\] Finally, genetic risk factors may predispose for vascular occlusive disease in patients treated with nilotinib or ponatinib; however, only little is known about these factors.\[[@ref18]\] Due to the relative rapid onset of vascular complications in patients under TKIs treatment (within 12 months after starting therapy), it has been hypothesized a direct effect of drugs on vascular cells.\[[@ref6]\] Some studies have postulated that TKIs can induce a vasospasm on rapid stenosis formations in arteries; however, now, there is a strong evidence about proatherogenic effects on endothelial cells.\[[@ref9][@ref19]\] It was demonstrated that nilotinib and ponatinib may promote the expression of proatherogenic surface adhesion receptors on human umbilical vein-derived endothelial cells *in vitro*.\[[@ref10][@ref20]\] Moreover, neoangiogenesis plays a pivotal role in vascular repair processes which are fundamental in favoring survival and recanalization of affected arteries. Both nilotinib and ponatinib have an antiangiogenic activity and inhibit proliferation and survival of human endothelial cells *in vitro*.\[[@ref20]\] In addition, nilotinib treatment resulted in an unbalanced pro-/anti-inflammatory network in a clinical cohort of patients who received either imatinib or nilotinib, which could lead to a proatherothrombotic predisposition, another possible driver of vascular complications.\[[@ref20]\] It was also reported that nilotinib might induce metabolic disorders, in particular, increased fasting glucose and cholesterol levels, associated with the increased risk of developing vascular occlusive events.\[[@ref21][@ref22][@ref23]\] Nilotinib treatment is also associated with hypothyroidism, which can affect lipid and glucose metabolism. Even if the exact cellular interactions and mechanism underlying nilotinib-induced hyperglycemia and hypercholesterolemia remain unknown, these metabolic changes can favor the development of atherosclerosis in patients with CML. Finally, all these spectrums of actions exerted by BRC-ABL TKIs can explain the elevated risk of PAD developments in patients treated with these drugs, especially if the previous mentioned risk factors are also present. Hypertension is a main side effect of all three major antivascular endothelial growth factor (VEGF) drugs (bevacizumab, sorafenib, and sunitinib). Mechanisms of arterial hypertension include both functional (inactivation of endothelial nitric oxide synthase and production of vasoconstrictors such as endothelin-1) and anatomic (capillary rarefaction) modifications, which lead to vasoconstriction and an increase in peripheral vascular resistance. All these effects may induce increased arterial stiffness, which increased risk of PAD, especially in patients who received TKIs. VEGF inhibitors (VEGFIs) are also associated with an absolute increase in risk of arterial and venous thrombosis and thromboembolism of 1.5%--4%.

###### 

Clinical risk factors contributing/predisposing to the occurrence of vascular adverse event in chronic myeloid leukemia patients treated with nilotinib or ponatinib

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Risk factors
  Predisposing genetic factors: Genetic variations predisposing to the occurrence of hypercholesterolemia or the development of diabetes mellitus
  Age and sex: Advanced age; males \>females
  Acquired somatic mutations: Clonal age-related hematopoiesis; clonal hematopoiesis of indeterminate potential (may predispose for development of CML as well as development of VAE)
  Lifestyle-related risk factors: Nicotine consumption; overweight/obesity; refused/irregular drug intake
  Preexisting overt comorbidities: Arterial hypertension, hypercholesterolemia, diabetes mellitus, thrombosis, stroke, other arteriopathies
  Dose of TKI and TKI sequence: Higher doses of nilotinib (800 mg/day) or ponatinib (45 mg/day); sequential exposure to nilotinib and ponatinib
  Time of TKI therapy: Longer exposure to nilotinib or ponatinib (most events occur after 12 months -- and VAE continue to accumulate over time)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Adapted from Valent P *et al*. Leukemia research. 2017. VAE=Vascular adverse event, TKI=Tyrosine kinase inhibitor, CML=Chronic myeloid leukemia

Diagnostic and therapeutic management {#sec2-2}
-------------------------------------

BCL-ABL kinase inhibitors have transformed the prognosis of CML; thus, many patients taking TKIs for CML will be on therapy for 10 years or longer. Therefore, it is essential for physicians to prevent and manage acute and chronic vascular complications associated with these agents. The first step in the prevention and diagnosis of PAD secondary to anticancer treatment is represented by accurate cardiovascular risk stratification, searching for preexisting CVRF and cardiovascular disease.\[[@ref24]\] Hence, the assessment of CVRF implemented by clinical visit and ankle--brachial index measurement is strongly recommended.\[[@ref1]\]

A simple ABCDE algorithm is an established tool to reduce cardiovascular events in the general population and has already been recommended to prevent cardiovascular disease in survivors of breast cancer. Similarly, Moslehi and Deininger\[[@ref25]\] proposed an ABCDE step to prevent cardiovascular disease in patients with CML treated with a TKI \[[Table 2](#T2){ref-type="table"}\]. This strategy allows identifying patients at higher risk of developing vascular complication and which can thus benefit of some precautions, such as selection of the optimal second- or third-line TKI and doses. Due to the high risk of development of PAD, it should be avoided to administrate nilotinib and ponatinib as a first-line therapy in patients with multiple CVRF if other agents are available.\[[@ref12]\]

###### 

ABCDE steps to prevent cardiovascular disease in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor

  Step
  ---------------------------------------------------------------------------------------------------
  Step A
   Awareness of cardiovascular disease signs and symptoms
   Aspirin (in select patients)
   Ankle-brachial index measurement at baseline and follow-up to document peripheral artery disease
  Step B
   Blood pressure control
  Step C
   Cigarette/tobacco cessation
   Cholesterol (regular monitoring and treatment, if treatment indicated)
  Step D
   Diabetes mellitus (regular monitoring and treatment, if treatment indicated)
   Diet and weight management
  Step E
   Exercise

Adapted from Moslehi JJ *et al*. J Clin Oncol 2015

In this context, different strategies have been proposed \[[Table 3](#T3){ref-type="table"}\]. One is to start with imatinib in most patients and to switch to second-line TKI only when a suboptimal or no response is seen or the patient is at high risk to transform to accelerated phase (AP)/blast phase (BP). Another possibility in high-risk patients (for both, AP/BP risk and vascular complication risk) is to start with bosutinib or to administer bosutinib after 3--6 months of imatinib therapy. An alternative is the possibility of inducing a stable molecular response (MR) with nilotinib, dasatinib or ponatinib, followed by 2 years of therapy with imatinib or bosutinib. However, this strategy does not prevent at all the possibilities of PAD development because usually, several months are necessary before reaching a deep MR. An interesting alternative can be the rotational therapy, consisting in a combination of a potent but high-risk TKI (nilotinib or ponatinib) with a safer agent (imatinib or bosutinib) in 1--3 month intervals.\[[@ref26][@ref27]\] All these strategies, however, need to be tested in large clinical randomized trial. Once PAD has occurred, the management relies first on the grade of vascular disease. In case of Fontaine stages I or II, patients require risk factor control and periodic clinical, metabolic, and hemodynamic follow-up.\[[@ref28]\] In these cases, it is possible to maintain therapy with nilotinib or ponatinib, usually at low doses. It could be suggested to start therapy with aspirin, and antidiabetic drugs or cholesterol-lowering agents, or antihypertensive drugs, could be added if metabolic disorders or hypertension develop. However, the development of high-grade PAD is a more challenging question, due to the problems related to interruption of potent BCR-ABL TKIs therapy. In some cases, it is possible to switch to TKIs with safer vascular profile (imatinib or bosutinib). In selected patients with deep and long-lasting MR (MR4 or deeper), discontinuation of TKI treatment may be an option. Moreover, revascularization should be individualized and discussed in a multidisciplinary meeting with experts in hematology, vascular surgery, and cardio-oncology.\[[@ref1][@ref29]\]

###### 

Proposed strategies to minimize the risk of vascular adverse event evolution in patients with chronic myeloid leukemia

  ------------------------------------------------------------------------------------------------------------------------------------------
  Pretreatment
   Selection of patients and selection of TKI based on comorbidities, cardiovascular risk factors, and the biology of CML
   Exclude patients with cardiovascular comorbidities from therapy with nilotinib and ponatinib
   Exclude patients with cardiovascular risk factors (high ESC score and molecular risk factors) from therapy with nilotinib and ponatinib
  During treatment (treatment algorithms, schedules, and dosing)
   Frontline use of imatinib in patients with CP CML
   Keep nilotinib and ponatinib exposure times to a minimum
   Reduce the dose of nilotinib or ponatinib if possible
   Avoid sequential application of nilotinib and ponatinib
   Switch to other TKI with lower risk concerning VAE development once a deep MR has been reached (prophylaxis)
   Switch to other TKI with lower risk concerning VAE development once a VAE has developed
  Alternative treatment concepts and comedication
   Discontinue TKI therapy after 2 years in deep MR (MR4 or deeper)
   SCT (young and fit patients)\*
   Antibody-based CML stem cell eradication followed by TKI discontinuation
   Discontinue TKI therapy and introduce immunotherapy or other experimental therapies as maintenance
   Prophylactic comedication with aspirin, gliptins, and statins
   TKI rotation therapy: Combining more toxic TKI with less toxic TKI
  ------------------------------------------------------------------------------------------------------------------------------------------

Adapted from Valent P *et al*. Leukemia research. 2017. \*In young and fit patients who are potential candidates for SCT, it is of considerable importance to avoid any occurrence of a VAE before SCT. Therefore, in these patients, it is as important to select optimal and safe therapy as in older patients with comorbidities. CP=Chronic phase, CML=Chronic myeloid leukemia, VAE=Vascular adverse event, TKI=Tyrosine kinase inhibitor, MR=Molecular response, ESC=European Society for Cardiology, SCT=Stem cell transplantation

In patients undergoing VEGFI, a practical algorithm has been recently proposed for assessing risk of hypertension and monitoring the occurrence of this complication during therapy \[[Table 4](#T4){ref-type="table"}\].\[[@ref24]\]

###### 

Cardiovascular risk assessment and monitoring during vascular endothelial growth factor inhibitors

  --------------------------------------------------------------------------------------------------------------
  Pretreatment cardiovascular risk assessment
   A thorough history: DM, cigarette smoking, preexisting HTN, HLD, CVD, previously documented LVH
   A thorough physical examination: Repeated BP measurements
   Laboratory and other tests: Chemistry including BUN, Cr, urine ACR, lipid profile, and baseline EKG
  During treatment
   BP \<140/90 mmHg at baseline→initiate VEGFI
    Home BP monitoring is recommended
    Check urine ACR every 3 months
    Avoid medications that are known to raise BP (such as erythropoietin, NSAIDs) if possible
    If development of HTN, see below
   BP \>140/90 at baseline→treat HTN based on current JNC7/8 guidelines and then start VEGFI if HTN controlled
   Not controlled HTN→hold or dose adjustment in these cases
    Uncontrolled HTN (SBP \>160 mmHg or DBP \>100 mmHg)
    Uncontrolled HF
    Unstable or poorly controlled angina
    Significant proteinuria or kidney dysfunction
    Uncontrolled arrhythmia
  --------------------------------------------------------------------------------------------------------------

Adapted from Li W *et al*. J Am Coll Cardiol 2015. ACR=Albumin creatinine ratio, BP=Blood pressure, BUN=Blood urea nitrogen, Cr=Creatinine; CVD=Cardiovascular disease, DM=Diabetes mellitus, EKG=Electrocardiogram, HTN=Hypertension, JNC=Joint National Committee, LVH=Left ventricular hypertrophy, NSAID=Nonsteroidal anti-inflammatory drug, VEGFI=Vascular endothelial growth factor inhibitors, SBP=Systolic blood pressure, DBP=Diastolic blood pressure

S[TROKE]{.smallcaps} {#sec1-3}
====================

Incidence and pathophysiology {#sec2-3}
-----------------------------

Stroke and transient ischemic attacks can occur in patients who have cancer with patterns and risk factors similar to noncancer patients. Although not at higher risk of hemorrhagic stroke, patients with cancer are at higher risk of thromboembolic events including those related to paradoxical embolization and indwelling catheters. Hypercoagulability may play a role in some patients but not in general. Moreover, cerebrovascular disease, such as transient ischemic attack and ischemic stroke, can complicate in particular head-and-neck radiotherapy \[[Table *5*](#T5){ref-type="table"}\]. The risk of stroke is, in fact, increased, at least doubled, after mediastinal, cervical, or cranial radiotherapy, with the exception of adjuvant neck radiotherapy for breast cancer where carotid exposure is minimal.\[[@ref30][@ref31]\] The risk of developing cerebrovascular disease is higher when radiotherapy exposure occurs in childhood than in adulthood. Radiation vasculopathy is the precursor to ischemic stroke in patients who have been treated with head-and-neck radiotherapy for cancer.\[[@ref32][@ref33]\] Chronic radiation vasculopathy affecting medium and large intra- and extra-cranial arteries is characterized by increasing rates of hemodynamically significant stenosis. The pathogenesis of radiation-induced cerebrovascular complication, however, is not totally known, and there are two main hypotheses. In particular, while some authors consider radiation occlusive vasculopathy as a form of accelerated atherosclerosis, others considered it as a distinct disease secondary to the initial radiation insult to the vasa vasorum.\[[@ref34][@ref35][@ref36][@ref37][@ref38]\] Fonkalsrud *et al*. analyzed the evolution of radiation vasculopathy in canine femoral arteries after a net dose of 40 Gray.\[[@ref39]\] By 48 h, there was extensive endothelial damage with nuclear disruption, platelet aggregation, and fibrin deposition; the intima and media remained intact, but the adventitia already showed minor fibrosis and hemorrhage. By 1 week, no normal endothelial cells were seen, and by 3 weeks, there was destruction of the internal elastic lamina and marked thickening of the endothelium. By 6 weeks, the media was hypocellular. By 4 months, there was focal necrosis and fibrosis of the media, accompanied by chronic inflammation and minimal thrombosis of the adventitia. The medial and adventitial fibrosis narrowed the vessel lumen. It is also known that irradiation induces an increase in oxidative stress involved in the formation of vascular damage. Some pro-inflammatory molecules (cytokines and growth factors) can stimulate radio-induced endothelial proliferation, fibroblast proliferation, collagen deposition, and hence the fibrosis leading to the development of atheromas. Endothelial damage secondary to irradiation induces the secretion of thrombomodulins, which, together with other pro-inflammatory molecules, increase the attraction of leukocytes on the endothelium (chemotaxis), resulting in subendothelial inflammatory infiltrate. The pathophysiology of radiation-induced vasculopathy can be, thus, summarized in the following mechanisms occurring in medium and large vessels: vasa vasorum occlusions with medial necrosis and fibrosis, adventitial fibrosis, and accelerated atherosclerosis, leading to increased carotid stiffness and intima--media thickness and advanced atherosclerosis (occurring \>10 years after radiotherapy).\[[@ref40][@ref41]\] However, while it is clear that no doses of radiotherapy can be considered safe, there is no exhaustive information if and which dose can be safer.

###### 

Radiation-induced vasculopathy

                    Vasculopathy
  ----------------- ---------------------------------------------------------------------------------------------
  Cause             Radiotherapy (mediastinal, cranial, and cervical)
  Physiopathology   Endothelial damage, fibrosis, medial necrosis, and accelerated atherosclerosis
  Location          Small vessels and medium or large vessels
  Evaluation        Clinical visit, ankle-brachial index, carotid duplex ultrasound
  Screening         5 years after radiation exposure, then every 5 years or earlier if atherosclerosis detected
  Treatment         Antiplatelet treatment; severe stenosis may require stenting or surgery

Even if radiotherapy is the main "iatrogenic" cause of cerebrovascular accident (CVA) in patients affected by cancer, it is not the only. Likewise, not all, but some chemotherapeutic agents and new target therapy have been associated with a risk of stroke in neoplastic patients. Cisplatin and 5-fluorouracil (5-FU) are the main drugs involved. More than 30 years ago, Goldhirsch *et al*.\[[@ref42]\] reported an acute CVA in a patient receiving a cisplatin-based treatment. Other case reports followed.\[[@ref43][@ref44][@ref45][@ref46]\] The physiopathogenesis is probably multifactorial. Cisplatin is responsible of a hypercoagulability state secondary to a cisplatin-induced reduction of C-reactive protein and increased von Willebrand factor and tissue factor level. This may explain why, in some cases, no cause of ischemic stroke can be identified; whereas, in other cases, local cranial artery thrombosis can occur to the point of acute complete occlusions.

Moreover, cisplatin induces endothelial dysfunction responsible of increased intima--media thickness and reduced production of nitric oxide\[[@ref47]\] and may cause nephrotoxicity with renal magnesium wasting that leads to vasoconstriction.\[[@ref46]\] 5-FU is an antineoplastic agent which has also been connected with increased incidence of ischemic strokes, and cases are also reported following combined treatment with both 5-FU and cisplatin.\[[@ref45][@ref48]\] It was demonstrated that 5-FU causes direct endothelium-independent vasoconstriction of vascular smooth muscle *in vitro*.\[[@ref45]\] However, ischemic stroke has to be differentiated from leukoencephalopathy with stroke-like presentation which is a rare complication of chemotherapeutic agents including 5-FU and is characterized by specific findings on cerebral magnetic resonance.\[[@ref49][@ref50][@ref51]\]

Given the outlined side effect profile of arterial thrombosis, bleeding, and hypertension, concerns for stroke risk have been raised for VEGFI. In Phase I and II trials of VEGFI, ischemic stroke and intracranial hemorrhage occurred at a rate of 1.9% each with bevacizumab and in 0% and 3.8% of patients receiving VEGF receptor TKIs, respectively.\[[@ref52]\]

A retrospective review of the Food and Drug Administration MedWatch database of adverse events indicated that cranial bleeds accounted for 12.9% of all bleeding events with bevacizumab (which were 6.8% of all adverse events) and were fatal in half of the cases.\[[@ref53]\]

The greatest risk actors were additional use of medications associated with bleeding and thrombocytopenia, whereas central nervous system tumors and metastases do not seem to increase the risk of intracranial bleeding. The combination of bevacizumab with 5-FU- or carboplatin-based therapies may more than double the overall incidence of arterial thromboembolic events, especially in those ≥65 years of age or with a previous arterial thromboembolic event.\[[@ref54]\]

In this analysis of combination therapies, as many as half of all acute ischemic events were strokes or transient ischemic attacks.\[[@ref55]\]

Structural vascular abnormalities such as atherosclerosis or dissections as underlying mechanisms are rarely reported. Finally, even if cases of CVA after treatment with bevacizumab were reported,\[[@ref56]\] the meta-analysis conducted by Ranpura *et al*. concluded for any increased relative risk of stroke with bevacizumab therapy.\[[@ref57]\] Similarly, although significant carotid artery disease can be noted with sorafenib, this seems to be the exception rather than the rule in patients presenting with stroke while undergoing therapy with VEGF signaling pathway TKIs. However, probably a higher risk of cerebral ischemic events has to be expected due to endothelial injury secondary to inhibition of VEGF signaling and subsequent risk of arterial thrombosis, typical of this group of drugs.\[[@ref58][@ref59]\]

Anthracyclines, more commonly associated with cardiac toxicity, may also increase the risk of stroke through several pathophysiological mechanisms involving carotid arteries such as oxidative stress, vascular inflammation, and apoptosis. Indeed, anthracyclines can induce both an acute and chronic carotid damage, the first related to endothelial dysfunction and increase of smooth muscle tone and the second to accelerated atherosclerosis and increased collagen synthesis. More than 15 years ago, experimental models demonstrated that the exposure of animal arteries to doxorubicine for 1 to 10 weeks is able to lead apoptosis of smooth muscle cells and increased medial and adventitial thickness, and these data were confirmed later.\[[@ref60]\] These reparative processes secondary to the chemical stress lead to structural changes within the vessel wall and extracellular matrix with increased collagen deposition and vessel wall calcification, ultimately resulting in reduced arterial compliance and increased stiffness. More recently, it has been detected through magnetic resonance imaging, in individuals receiving anthracyclines for breast cancer, an early (≈3 months) and abrupt increase of arterial stiffness, and interestingly, this effect was dose, age, and CVRF independent. Moreover, the increase of arterial stiffness can be persistent at 12 months after therapy.\[[@ref61][@ref62][@ref63]\] Furthermore, patients survived for ≥5 years after diagnosis of leukemia, lymphomas, central nervous system tumors, and sarcomas of leukemia treated with standard chemotherapy show lower carotid distensibility and compliance, indicating increased arterial stiffness when compared to controls.\[[@ref64]\] All these results demonstrate thus that early in life, cancer survivors previously treated with anthracyclines have arterial changes indicating increased risk for premature atherosclerosis and stroke.

An increased incidence of stroke has been demonstrated in patients with multiple myeloma (MM) undergoing immunomodulatory drugs such as thalidomide, lenalidomide, and pomalidomide. These agents inhibit the production of interleukin-6 (IL-6), which is a growth factor for MM cells. They also activate apoptotic pathways through caspase-8-mediated cell death and regulate the activity of molecules that affect apoptosis through c-Jun terminal kinase-dependent release of cytochrome-c and SMAC into the cytosol of cells. The exact mechanism of the increased clot risk with this class of agents is not known. It has been suggested that this is a direct effect of the drugs on endothelial cell activation, and this is possibly synergistic with the increased risk of thrombosis related to MM. The latter may be mediated by increased IL-6 and tumor necrosis factor-alpha found in MM.\[[@ref65]\]

A moyamoya disease-like process has also been implied as a potential side effect of interferon-α. A posterior reversible encephalopathy syndrome can emerge as an acute cerebral event with headache, confusion, visual symptoms, and seizures. The characteristic finding is posterior cerebral white matter edema on neuroimaging attributable to impaired autoregulation of the cerebral vasculature. It is often noted with severe hypertension, and numerous cases have been reported for patients who have cancer undergoing drug therapy, in particular, with VEGFI and the proteasome inhibitor bortezomib.\[[@ref66]\]

Diagnostic and therapeutic management {#sec2-4}
-------------------------------------

Patients treated with head and/or neck radiotherapy should undergo cerebrovascular ultrasound, especially beyond 5 years after irradiation, and then follow-up should be performed at least every 5 years or earlier if atherosclerosis is detected.\[[@ref1]\] Of note, carotid lesions secondary to radiotherapy are often more extensive and commonly involve longer segments of the carotid arteries. Computed tomography angiography is, also, routinely used to evaluate carotid, subclavian, and aortic diseases related to radiation therapy.\[[@ref67]\] To date, no randomized trial has assessed the medical treatment option for primary or secondary stroke prevention in this patients\' group. A strict control of traditional CVRF should be strongly recommended, and antiplatelet treatment may be considered. Significant carotid stenosis may be treated by surgery or stenting.\[[@ref29][@ref68][@ref69][@ref70][@ref71]\] Even if neither approach appears to be clearly superior, different studies showed a higher incidence of restenosis after carotid angioplasty and stenting of radiation-induced vascular stenosis, compared to surgical results.\[[@ref72][@ref73][@ref74]\]

The relationship linking increased arterial stiffness with atherosclerosis and risk of stroke is well recognized. Accordingly, it is reasonable to advocate that efforts should be directed at monitoring increased arterial stiffness and managing CVRF in cancer patients treated with drugs which may potentially impair vascular elasticity (i. e., anthracyclines and anti-VEGFR). Applanation tonometry and/or echotracking are two main available modalities in clinical practice for this purpose\[[@ref75]\] \[[Figure 1](#F1){ref-type="fig"}\]. Moreover, being Pulse wave velocity (PWV), an independent predictor of cardiovascular morbidity and stroke, we can better stratify patients\' prognosis. Nonetheless, larger prospective studies are needed to determine the predictive value of PWV in this population and its utility as a screening modality. Unsolved problems on this issue are detailed in [Table 6](#T6){ref-type="table"}.

![Measurement of beta-index and PWV through echotracking at baseline and 3 months after starting chemotherapy with anthracyclines, showing increased arterial stiffness at 3-month follow-up](JCE-30-17-g001){#F1}

###### 

Unsolved problem for including arterial stiffness assessment within the stoke risk management in cancer patients

  ---------------------------------------------------
  Small studies, small patients
  Age, race, and gender effects
  Reversibility
  Cancer-related effect on vessels
  No studies drug specific (often combined therapy)
  Radiotherapy additional effects
  Comorbidities
  Unknown relationship with outcome
  Short follow-up studies
  ---------------------------------------------------

In patients at risk of ischemic stroke, undergoing treatment with platinum compounds is important to manage CVRF to prevent vascular ischemia. Carboplatin, second-generation platinum, shows an improved toxicity profile. Additional agents, for example, vitamins, selenium, resveratrol, and melatonin reduce endothelial cell oxidative stress and inhibit inflammation, thus exerting beneficial effects by suppressing cisplatin-related oxidative injury.\[[@ref46]\]

Patients with cancer who have signs or symptoms of stroke should be managed based on published guidelines.\[[@ref76]\] This entails a a head computed tomography to address the question of a hemorrhagic event or intracranial tumors (metastases). If negative, the decision on revascularization is to be made. Importantly, patients with cancer *per se* are not at a higher risk of intracerebral hemorrhage when undergoing thrombolytic therapy. However, patients who experience a thrombotic stroke as a consequence of chemotherapy have not been rigorously studied in fibrinolysis trials. Low platelet count (\<100,000) and abnormal plasma glucose (\<50 or \>400 mg/dL) are contraindications to lytic therapy that can be quite relevant for patients who have cancer. Further, workup of underlying pathologies such as thrombotic occlusion, critical stenosis, or dissection by imaging of the cerebral vasculature should be pursued on as needed. A 12-lead ECG should be obtained to assess for atrial fibrillation and an echocardiogram to assess for a patent foramen ovale, valve abnormalities, regional wall abnormalities, and aneurysms as potential sources of thromboembolism. An emergency neurology referral should be made at the onset of presentation. Care decisions (acute and long term) are to be made in the context of the patients\' overall prognosis.\[[@ref66]\]
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